Clinical trials: Pleural Mesothelioma
Lung Adenocarcinoma, Ovarian Cancer
CAR T Cells in Mesothelin Expressing Cancers
Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.
- Conditions
- Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT03054298
- Testing
- huCART-meso cells
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Pennsylvania
Mesothelioma
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
Background: Mesothelioma is cancer of the tissue that lines some organs. A new drug, LMB-100, may bind to a protein on mesothelioma tumors and kill cancer cells.
- Trial name
- NCT03436732
- Testing
- LMB-100, SEL-110
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
The objective of this study is to determine whether MEDI4736 or combination therapy with MEDI4736 + tremelimumab are associated with favorable alterations of the intratumoral immunologic environment in subjects undergoing…
- Trial name
- NCT02592551
- Testing
- MEDI4736, Tremelimumab, no other name
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Advanced Malignant Mesothelioma, Recurrent Malignant Mesothelioma
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura.
- Trial name
- NCT00392444
- Testing
- sunitinib malate
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Pleural Mesothelioma Malignant Advanced
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
Trial comparing standard treatment (chemotherapy) with pembrolizumab treatment in patients with advanced pretreated malignant mesothelioma.
- Trial name
- PROMISE-meso (NCT02991482)
- Testing
- Pembrolizumab, Gemcitabine, Vinorelbine
- Where
- 15 sites in Spain, Switzerland and 1 more
- Volunteers
- 144 people
- Sponsor
- ETOP IBCSG Partners Foundation
Mesothelioma, Malignant
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
This study was originally designed as a multicenter, double-blind, randomized, parallel-group study, using a placebo control or amatuximab 5 milligrams per kilogram (mg/kg), administered weekly, designed to evaluate the safety…
- Trial name
- ARTEMIS (NCT02357147)
- Testing
- Amatuximab, Pemetrexed, Cisplatin
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 124 people
- Sponsor
- Morphotek
Mesothelioma
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer.
- Trial name
- NCT02784171
- Testing
- Cisplatin, Pemetrexed, Pembrolizumab
- Where
- 57 sites in Canada, France and 1 more
- Volunteers
- 520 people
- Sponsor
- Canadian Cancer Trials Group
Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma.
- Conditions
- Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8
- Trial name
- NCT04158141
- Testing
- Carboplatin, Cisplatin, Decortication
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- NRG Oncology
Malignant Pleural Mesothelioma
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Study of galinpepimut-S, a Wilms Tumor-1 (WT1) vaccine, to see if it delays or prevents the mesothelioma from growing back after surgery. WT1 is a protein in cancer cells that regulates gene expression and causes cell growth.
- Trial name
- NCT01265433
- Testing
- Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sellas Life Sciences Group
Mesothelioma, Malignant
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
MiST is a British Lung Foundation funded, University of Leicester Study, a multi-arm stratified therapy based clinical trial for patients with relapsed mesothelioma.
- Trial name
- MiST (NCT03654833)
- Testing
- Rucaparib, Abemaciclib, pembrolizumab & bemcentinib
- Where
- United Kingdom
- Volunteers
- 186 people
- Sponsor
- University of Leicester
Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
This phase I/II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that…
- Conditions
- Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma
- Trial name
- NCT02535312
- Testing
- Cisplatin, Methoxyamine, Pemetrexed Disodium
- Where
- 14 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Biphasic Mesothelioma, Epithelioid Mesothelioma
Pembrolizumab in Treating Patients With Malignant Mesothelioma
This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum).
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma
- Trial name
- NCT02399371
- Testing
- Pembrolizumab, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Chicago
Pleural Mesothelioma
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
The primary objective of the study is to determine the feasibility (as determined by lack of serious adverse events) and tolerability (as determined by patient's ability to complete the study) of a multimodal lung sparing regimen…
- Trial name
- NCT00859495
- Testing
- Doxorubicin, Cisplatin, Pemetrexed
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Columbia University
Mesothelioma
Nintedanib (BIBF 1120) in Mesothelioma
This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin…
- Trial name
- NCT01907100
- Testing
- Nintedanib, Pemetrexed, Cisplatin
- Where
- 123 sites in United States, Argentina and 25 more
- Volunteers
- 545 people
- Sponsor
- Boehringer Ingelheim
Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
This is an open-label, multicenter, phase 1/2 study of BBI608 in combination with pemetrexed and cisplatin chemotherapy as a 1st line treatment for Malignant Pleural Mesothelioma (MPM).
- Trial name
- NCT02347917
- Testing
- BBI608, Pemetrexed, Cisplatin
- Where
- 2 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Leukemia, Lung Cancer
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from…
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes
- Trial name
- NCT00398138
- Testing
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma
Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma
This pilot phase 0 trial studies accelerated hypofractionated radiation therapy immediately before surgery in treating patients with malignant pleural mesothelioma (cancer in the thin layer of tissue that covers the lungs and…
- Trial name
- NCT02672033
- Testing
- Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Pleural Mesothelioma
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy.
- Trial name
- NCT03175172
- Testing
- CRS-207, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Aduro Biotech, Inc.
Malignant Pleural Mesothelioma
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
This study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma…
- Trial name
- INFINITE (NCT03710876)
- Testing
- rAd-IFN, Celecoxib Oral Product, Gemcitabine
- Where
- 29 sites in United States, Australia and 7 more
- Volunteers
- 53 people
- Sponsor
- Ferring Ventures Limited
Mesothelioma, Pleural Mesothelioma
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Patients with pleural mesothelioma that can not be surgically removed will receive durvalumab, in combination with standard chemotherapy of pemetrexed and cisplatin as first-line treatment.
- Trial name
- PrE0505 (NCT02899195)
- Testing
- Durvalumab
- Where
- 20 sites in United States
- Volunteers
- 55 people
- Sponsor
- PrECOG, LLC.